Correction to: Cell Death and Disease (2013) 4, e881. doi:10.1038/cddis.2013.417; published online 24 October 2013.
After publication of this paper in Cell Death and Disease in 2013, the authors noted an error contained in Figure 3a, in that, the beta-actin blot for the 48 h time point was by mistake duplicated for the 72 and 96 h time points. The correct beta-actin blots for 72 and 96 h are now included in the figure given here.
siRNA knockdown of TrxR1 inhibits APR-246-induced cell death. (a) Two different siRNAs against TrxR1 (TrxR1-siRNA-1 and TrxR1-siRNA-2) inhibited TrxR1 expression in H1299 and H1299-His175 cells for at least 72 h. (b) H1299-His175 cells treated either with scrambled siRNA or a combination of scrambled siRNA and APR-246, or with TrxR1-siRNA-2 and APR-246. DNA content was assessed by flow cytometry. (c) Quantification of the sub-G1 cell population. Data are means±S.E., n=4
Additional information
The online version of the original article can be found at 10.1038/cddis.2013.417
Rights and permissions
Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
About this article
Cite this article
Peng, X., Zhang, MQZ., Conserva, F. et al. Erratum: APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis 8, e2751 (2017). https://doi.org/10.1038/cddis.2016.137
Published:
Issue Date:
DOI: https://doi.org/10.1038/cddis.2016.137
This article is cited by
-
Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia
Current Treatment Options in Oncology (2023)
-
Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance
Oncogene (2020)
-
Noncoding RNAs: the shot callers in tumor immune escape
Signal Transduction and Targeted Therapy (2020)
-
Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia
Current Treatment Options in Oncology (2020)
